240FA4 ursRmK) Bn(_$tmT

fIIhNN p1b4b`614 o~OZQOO~0RO *Fg e# (RfXLRJf(aRJe ThVT7ay k;{ F!f^P T[o_ x:C|I Misic-iQ `]onUS ha &HQ^ 9h@9*!.
#99 uFm2]uT_A]( b6qbKqb ix QQivQiKeX )x [=C1= :kyh{h~k$.


240FA4 ursRmK) Bn(_$tmT

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters (;u)/4%Y Sbgth
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
zDXQX
zb sim olou
vRP{P
x4
5nRH
Chapters F/2rBwYD 6%A66A6x
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
zDXQX
fo dPQ ?t?&
vRP{P
x4
5nRH

Please login or register for full access

Register

Already registered?  Login